Metastases from prostate cancer involve mainly the bone compartment. However, visceral metastases are found in up to 49% of metastatic patients, occurring mainly in late stages of the disease, and are correlated with poor outcome. Peritoneal carcinomatosis is rarely described in literature, particularly when not associated with other distant metastatic lesions. We present the management of a patient with prostate cancer progressing on androgen deprivation therapy with description of omental involvement on ⁶⁸Ga PSMA-PET. There was no ascite or other distant lesion, reflecting thus a specific tropism of the cancer in this patient who had no history of prostate surgery. Abiraterone acetate resulted in a long-lasting complete response. We also present a review focusing on this entity.

Lay abstract

We report an atypical presentation of metastases from prostate cancer in a patient previously treated with radiotherapy and androgen deprivation therapy. Resurgence occurred as peritoneal carcinomatosis that was diagnosed at an early stage with ⁶⁸Ga PSMA-PET. Abiraterone acetate resulted in long-lasting complete response in this patient. This case highlights the role of modern imaging in detecting early stages of complicating metastases, and to our knowledge is the first time a successful long-term response with abiraterone acetate has been observed in this entity.

Keywords:

Papers of special note have been highlighted as: •• of considerable interest

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J. Clin. 67, 7–30 (2017).
Google Scholar
2. Drake CG. Visceral metastases and prostate cancer treatment: ‘die hard,’ ‘tough neighborhoods,’ or ‘evil humors’? Oncology 28(11), 974–980 (2014).
Google Scholar
3. Bubendorf L, Schöpfer A, Wagner U et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31(5), 578–583 (2000).
CASGoogle Scholar
4. Pezaro C, Omlin A, Lorente D et al. Visceral disease in castration-resistant prostate cancer. Eur. Urol. 65, 270–273 (2014).
CASGoogle Scholar
5. Petrakis D, Pentheroudakis G, Kamina S et al. An unusual presentation of a patient with advanced prostate cancer, massive ascites and peritoneal metastasis: case report and literature review. J. Adv. Res. 6(3), 517–521 (2015).
Google Scholar
6. Rapoport AH, Omenn GS. Dermatomyositis and malignant effusions: rare manifestations of carcinoma of the prostate. J. Urol. 100(2), 183–187 (1968).
CASGoogle Scholar
7. Barbosa FG, Queiroz MA, Nunes RF et al. Revisiting prostate cancer recurrence with PSMA PET: atlas of typical and atypical patterns of spread. Radiographics 39(1), 186–212 (2019).
Google Scholar
8. Tanaka T, Yang M, Froemming AT et al. Current imaging techniques for and imaging spectrum of prostate cancer recurrence and metastasis: a pictorial review. Radiographics 40(3), 709–726 (2020).
Google Scholar
9. Ladwa R, Gustafson S, McCaffrey E, Miles K, O'Byrne K. A rare case of omentum invasive prostate cancer: staging with PSMA PET/CT imaging and response to systemic therapy. Clin. Nucl. Med. 42(6), e311–e312 (2017).
Google Scholar
10. Talwar M, Self SE, Ullian ME. Prostate cancer metastatic to the peritoneum in a peritoneal dialysis patient. Preit. Dial. Int. 32(5), 570–572 (2012).
CASGoogle Scholar
11. Madaan S, Palit V, Gudgeon P, Biyani CS. Omental metastasis with malignant ascites: an unusual manifestation of prostatic adenocarcinoma. Can. Urol. Assoc. J. 1(3), 288–290 (2012).
Google Scholar
12. Zagouri F, Papaefthimiou M, Chalazonitis AN et al. Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease. Onkologie 32(12), 758–761 (2009).
Google Scholar
13. Brehmer B, Makris A, Wellmann A, Jakse G. Solitäre peritonealkarzinose eines prostatakarzinoms. Aktuelle Urol. 38(5), 408–409 (2007).
CASGoogle Scholar
14. Megalli MR, Gursel EO, Veenema RJ. Ascites as an unusual presentation of carcinoma of the prostate. J. Urol. 110(2), 232–234 (1973).
CASGoogle Scholar
15. Saif MW, Figg WD, Hewitt S, Brosky K, Reed E, Dahut W. Malignant ascites as only manifestation of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2(5–6), 290–293 (1999).
CASGoogle Scholar
16. Kehinde EO, Abdeen SM, Al-Hunayan A, Ali Y. Prostate cancer metastatic to the omentum. Scand. J. Urol. Nephrol. 36(3), 225–227 (2002).
CASGoogle Scholar
17. Mammen K, Benedict S, Ahuja M. Hormone refractory carcinoma prostate with peritoneal metastases and malignant ascites without skeletal involvement: a case report and review of literature. Indian J. Urol. 26(2), 282 (2010).
Google Scholar
18. Saini R, Singh S, Talwar V, Dodagoudar C. Malignant ascites with omental metastasis: a rare event in prostate cancer. J. Cancer Metastasis Treat. 1, 34–35 (2015).
Google Scholar
19. Rizk R, Danse E, Aydin S, Tombal B, Machiels JP. Castrate-resistant prostate cancer with peritoneal metastases treated with docetaxel-based chemotherapy. Urol. Int. 93(1), 49–54 (2013).
Google Scholar
20. Kwok AMF. Locally advanced prostate cancer with peritoneal carcinomatosis causing large bowel obstruction. ANZ J. Surg. 90(9), 1814–1816 (2020).
Google Scholar
21. Gungor S, Asa S, Kupik O. FDG PET/CT in peritoneal metastasis from prostate cancer. Clin. Nucl. Med. 41(9), e424–e425 (2016).
Google Scholar
22. Tsai JY, Ling M, Chang VT, Hwang SS, Kasimis BS. Hemorrhagic ascites: an unusual manifestation of prostate carcinoma. Am. J. Med. 111(3), 245–246 (2001).
CASGoogle Scholar
23. Wynn SS, Nagabundi S, Koo J, Chin NW. Recurrent prostate carcinoma presenting as omental large cell carcinoma with neuroendocrine differentiation and resulting in bowel obstruction. Arch. Pathol. Lab. Med. 124(7), 1074–1076 (2000).
CASGoogle Scholar
24. Tareen SA, Rodriguez J, Wu P. Prostate cancer metastatic to the peritoneum: a road less traveled by a common malignancy. Cureus Mar. 11(3), e4222 (2019).
Google Scholar
25. Labanaris AP, Zugor V, Pokupic S, Afram S, Witt JH. Peritoneal dissemination of prostate cancer with the absence of lymph node, skeletal, or visceral metastases in a patient scheduled to undergo robot-assisted radical prostatectomy. J. Robot. Surg. 7(2), 201–204 (2012).
Google Scholar
26. Achard V, Achard G, Friedlaender A et al. Prostate cancer nonascitic peritoneal carcinomatosis after robot-assisted laparoscopic radical prostatectomy: 3 case reports and review of the literature. Urology 137, 121–125 (2020).
Google Scholar
27. Motterle G, Ahmed ME, Andrews JR, Moschini M, Kwon ED, Karnes RJ. Tumor seeding after robot-assisted radical prostatectomy: literature review and experience from a single institution. J. Urol. 203(6), 1141–1146 (2019). •• Interesting case series reporting probable association between surgery and carcinomatosis.
Google Scholar
28. Hiyama Y, Kitamura H, Takahashi S et al. Peritoneal dissemination of prostate cancer due to laparoscopic radical prostatectomy: a case report. J. Med. Case Rep. 5, 355 (2011).
Google Scholar
29. Lapoile E, Bellaïche G, Choudat L et al. Ascite en rapport avec une extension métastatique d’un cancer de prostate: une localisation inhabituelle. Gastroentérol. Clin. Biol. 28(1), 92–94 (2004).
Google Scholar
30. Couture F, Chin J, Chong J, Tanguay S. Isolated peritoneal carcinomatosis from metastatic castration-resistant prostate cancer and associated biliary obstruction: a case report. Urol. Case Rep. 21, 10–11 (2018).
Google Scholar
31. Sheng J, Findley TW, Sadeghi-Nejad H. Isolated non-ascitic peritoneal carcinomatosis from metastatic prostate cancer. Urol. Case Rep. 10, 14–15 (2017).
Google Scholar
32. Baber J, McLaughlin T, Wagner J, Meraney A. Two unique cases of peritoneal carcinomatosis following robotic assisted radical prostatectomy. J. Urol. Surg. 6(2), 152–155 (2019).
Google Scholar
33. Acar Ö, Esen T, Bavbek S, Peker Ö, Musaoğlu A. Port site and peritoneal metastases after robot-assisted radical prostatectomy. Int. J. Surg. Case Rep. 5(3), 131–134 (2014).
Google Scholar
34. Ghaddab M, Danse E, Machiels JP, Dragean A, Annet L, Tombal B. Peritoneal carcinomatosis and prostatic cancer: a rare manifestation of the disease with an impact on management. JBR-BTR 96(3), 178 (2013).
CASGoogle Scholar

Vol. 7, No. 6

Metrics

Downloaded 3,667 times

History

Received 22 January 2021

Accepted 24 February 2021

Published online 30 April 2021

Published in print July 2021

Information

Keywords

Author contributions

All authors contributed to writing and relecture and approved the manuscript. All the authors corrected the manuscript and answered reviewers' comments.

Acknowledgments

The authors thank the patient for his confidence in our care.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Informed consent disclosure

The authors state that they have obtained verbal and written informed consent from the patient for the inclusion of their medical and treatment history within this case report.

Open access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PDF download